Tissue and Stem Cell Therapeutics: Breakthroughs for Regenerative Medicine
Cell and Gene Therapy for Neurological Indications
Autologous Cell Therapies: New Developments in Cell-Based Immunotherapy
Gene Therapies Entering the Mainstream – What Are the Next Gene Therapy Treatments?
CAR-T Therapies: 10 Years On and the Future of CAR-T
Cell and Gene Therapy for Autoimmune Disorders
Gene Therapies: Advancing Curative Medicines for Rare and Genetic Disease
Allogeneic Cell Therapies: How Do We Get Off-The-Shelf Therapies Off The Ground?

Tissue and Stem Cell Therapeutics: Breakthroughs for Regenerative Medicine

20 Jan 2023
Modalities and Indications Track

11:00am Chair Introduction

John Rasko, Professor, University of Sydney


11:05am Presentation: TBA

Chris Min, Chief Executive Officer, Longeveron


11:20am Presentation: TBC

 Speaker TBC


11:35am Presentation: Tissue Therapeutics: Extending the Power of DNA and Cell-Based Approaches to Engineer Whole Tissues as Novel Therapeutics 

  • Built on 20+ years of research, this new class of regenerative medicine turns virtually any cell type into implantable bioengineered tissue
  • Tissue Therapeutics provides the adaptive and comprehensive cellular response needed to restore, repair or replace critical organ function impacted by progressive failures across multiple systems
  • Satellite Bio’s platform is positioned to address a broad range of complex diseases, replicating the high efficacy but reducing many of the complicating issues of the cell and gene approaches that have come before

Dave Lennon, Chief Executive Officer, Satellite Bio


11:50am Presentation: TBA

Jaeseung Lim, Chief Executive Officer and Chief Scientific Officer, Cellatoz Therapeutics


12:05pm Closing Panel with Q&A

With all session participants


Chris Min
Chief Executive Officer & Chief Medical Officer
Dave Lennon
Chief Executive Officer
Satellite Bio
Jaeseung Lim
Chief Executive Officer & Chief Scientific Officer
Cellatz Therapeutics
John Rasko
University of Sydney